NEW YORK, NY / ACCESSWIRE / January 9, 2024 / Weiss Law, a national shareholder rights law firm, is investigating possible breach of fiduciary duty and violation of the federal securities laws by the Board of Directors and senior officers of Akero Therapeutics, Inc. (NASDAQ:AKRO) ("Akero" or the "Company"), concerning the Company's development of efruxifermin to treat nonalcoholic steatohepatitis (NASH) patients with severe liver disease.
If you own Akero shares and wish to discuss this investigation, or share information which you have, or if you have any questions concerning this notice or your rights or interests, visit our website at
https://www.weisslaw.co/news-and-cases/akro
Or contact:
Josh Rubin, Esq.
stocks@weisslaw.co
(212) 682-3025
THERE IS NO COST OR OBLIGATION TO YOU
According to numerous news sources, the Company's drug performance fell short of its primary endpoint versus the placebo group in a phase 2b midstage study finding mixed statistically significant improvement after 36 weeks in patients receiving efruxifermin for the treatment of compensated cirrhosis due to nonalcoholic steatohepatitis, or NASH. On this news, the Company's stock price dropped from $48.54 on October 9 to close at $18.15 per share on October 10, 2023, a 60% decline. Analysts have correspondingly significantly reduced their stock price targets for the Company.
Weiss Law has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties. We have recovered over a billion dollars for defrauded clients. For more information about the firm, please go to: http://www.weisslaw.co
SOURCE: Weiss Law
View the original
press release on accesswire.com
